Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Next Deadline
132 days remaining
Statement of Use Due - Extension 4 Granted
Due Date
November 30, 2025
Extension Available
Until May 30, 2024
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 30, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| May 30, 2025 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| May 20, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| May 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 19, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 7, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 7, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 7, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 7, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 15, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 14, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 14, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 14, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 21, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 17, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 17, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 30, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 4, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 4, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 15, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 25, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 24, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 23, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 23, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 22, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 22, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 22, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 20, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 13, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 13, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jul 13, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 4, 2021 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 3, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 18, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
Class 040
custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells, in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease
Class 042
medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of, therapeutic targets for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of cancer, inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information relating to treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services
Additional Information
Design Mark
The mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border.
Pseudo Mark
A TWO BIO
Classification
International Classes
005
040
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"